217 related articles for article (PubMed ID: 27483186)
1. Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.
Zhang Y; Zhang D; Tian H; Jiao Y; Shi Z; Ran T; Liu H; Lu S; Xu A; Qiao X; Pan J; Yin L; Zhou W; Lu T; Chen Y
Mol Pharm; 2016 Sep; 13(9):3106-18. PubMed ID: 27483186
[TBL] [Abstract][Full Text] [Related]
2. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
3. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
Hu C; Dong X
Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
[TBL] [Abstract][Full Text] [Related]
4. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
5. Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα.
Borsari C; Keles E; McPhail JA; Schaefer A; Sriramaratnam R; Goch W; Schaefer T; De Pascale M; Bal W; Gstaiger M; Burke JE; Wymann MP
J Am Chem Soc; 2022 Apr; 144(14):6326-6342. PubMed ID: 35353516
[TBL] [Abstract][Full Text] [Related]
6. A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
Ábrányi-Balogh P; Petri L; Imre T; Szijj P; Scarpino A; Hrast M; Mitrović A; Fonovič UP; Németh K; Barreteau H; Roper DI; Horváti K; Ferenczy GG; Kos J; Ilaš J; Gobec S; Keserű GM
Eur J Med Chem; 2018 Dec; 160():94-107. PubMed ID: 30321804
[TBL] [Abstract][Full Text] [Related]
7. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
8. Electrophilic fragment-based design of reversible covalent kinase inhibitors.
Miller RM; Paavilainen VO; Krishnan S; Serafimova IM; Taunton J
J Am Chem Soc; 2013 Apr; 135(14):5298-301. PubMed ID: 23540679
[TBL] [Abstract][Full Text] [Related]
9. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
Agarwal SM; Pal D; Gupta M; Saini R
Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
[TBL] [Abstract][Full Text] [Related]
10. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
11. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
12. How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor-Williams E; Rowley CN
J Chem Inf Model; 2018 Sep; 58(9):1935-1946. PubMed ID: 30118220
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent, selective, covalent inhibitors of JAK3.
Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
[TBL] [Abstract][Full Text] [Related]
14. An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases.
Petri L; Egyed A; Bajusz D; Imre T; Hetényi A; Martinek T; Ábrányi-Balogh P; Keserű GM
Eur J Med Chem; 2020 Dec; 207():112836. PubMed ID: 32971426
[TBL] [Abstract][Full Text] [Related]
15. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles.
Serafimova IM; Pufall MA; Krishnan S; Duda K; Cohen MS; Maglathlin RL; McFarland JM; Miller RM; Frödin M; Taunton J
Nat Chem Biol; 2012 Apr; 8(5):471-6. PubMed ID: 22466421
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments.
Petri L; Ábrányi-Balogh P; Tímea I; Pálfy G; Perczel A; Knez D; Hrast M; Gobec M; Sosič I; Nyíri K; Vértessy BG; Jänsch N; Desczyk C; Meyer-Almes FJ; Ogris I; Golič Grdadolnik S; Iacovino LG; Binda C; Gobec S; Keserű GM
Chembiochem; 2021 Feb; 22(4):743-753. PubMed ID: 33030752
[TBL] [Abstract][Full Text] [Related]
17. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
18. Covalent docking of large libraries for the discovery of chemical probes.
London N; Miller RM; Krishnan S; Uchida K; Irwin JJ; Eidam O; Gibold L; Cimermančič P; Bonnet R; Shoichet BK; Taunton J
Nat Chem Biol; 2014 Dec; 10(12):1066-72. PubMed ID: 25344815
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion.
Carmi C; Lodola A; Rivara S; Vacondio F; Cavazzoni A; Alfieri RR; Ardizzoni A; Petronini PG; Mor M
Mini Rev Med Chem; 2011 Oct; 11(12):1019-30. PubMed ID: 21861809
[TBL] [Abstract][Full Text] [Related]
20. Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity.
Lonsdale R; Burgess J; Colclough N; Davies NL; Lenz EM; Orton AL; Ward RA
J Chem Inf Model; 2017 Dec; 57(12):3124-3137. PubMed ID: 29131621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
